Sulazepam, a benzodiazepine, is a selective ovarian cancer G protein-coupled receptor (OGR1) agonist. Sulazepam has anticonvulsive action and has the potential for airway hyperresponsiveness (AHR) research.

Sulazepam (3.2 mg/kg in 25 µL via intranasal route ∼30 min before HDM challenge; 5 days a week for three consecutive weeks) inhibits the development of airway hyperresponsiveness (AHR) in Male and female wild-type C57BL/6 mice (8-10 wk old), but not in age-matched OGR1KO mice (C57BL/6 background) with house dust mite (HDM) allergen (25 μg; intranasally).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Sulazepam (3.2 mg/kg in 25 µL via intranasal route ∼30 min before HDM challenge; 5 days a week for three consecutive weeks) inhibits the development of airway hyperresponsiveness (AHR) in Male and female wild-type C57BL/6 mice (8-10 wk old), but not in age-matched OGR1KO mice (C57BL/6 background) with house dust mite (HDM) allergen (25 μg; intranasally).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Ajay P Nayak, et al. OGR1-dependent regulation of the allergen-induced asthma phenotype. Am J Physiol Lung Cell Mol Physiol. 2021 Dec 1;321(6):L1044-L1054.  [Content Brief]

  . Tonio Pera, et al. Biased signaling of the proton-sensing receptor OGR1 by benzodiazepines. FASEB J. 2018 Feb;32(2):862-874.  [Content Brief]